Based on these data, all the experts agreed that in NSCLC patients with high PD-L1 expression (≥50%) and PS score ≤ 1, first-line treatment with AT, CEMI, or PEMBRO should be considered (statement 7, Table 1). Here, CD274 is linked to non-small cell lung carcinoma.